• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与Xience支架相比,卡塔尼亚支架在接受血管成形术患者中的不良后果:一项双盲随机对照试验。

Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial.

作者信息

Pourmoghaddas Masoud, Rohani Hamid Reza, Sanei Hamid, Amirpour Afshin

机构信息

Isfahan Cardiovascular Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.

出版信息

Adv Biomed Res. 2017 Nov 30;6:154. doi: 10.4103/2277-9175.219419. eCollection 2017.

DOI:10.4103/2277-9175.219419
PMID:29285484
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5735554/
Abstract

BACKGROUND

The present study tries to compare the unintended outcomes of the Catania stent versus Xience stent in patients undergoing angioplasty.

MATERIALS AND METHODS

In a three month, follow-up, double-blinded, randomized controlled trial, 83 patients undergoing angioplasty, who met the inclusion criteria were entered into the study. After randomization 43 patients were treated with the Xience stent and 40 patients with the Catania stent. Stent-related outcomes such as Cardiac and Non-Cardiovascular Death, Myocardial Infarction (MI), Target Lesion Revascularization (TLR), Stent Thrombosis (ST), Coronary Artery Bypass Grafting (CABG), Peripheral vasculopathy, and Cerebral Vascular Accident (CVA) were compared between the groups.

RESULTS

There was no statistically significant difference in the incidence rate of complications and clinical outcomes between the two treatment groups ( > 0.05). The incidence of MI, TLR, CABG operation, peripheral vasculopathy, or CVA was not observed in any patient and there was no statistically difference in mortality (4.7% vs. 2.5%; = 0.527) and stent thrombosis (2.3% vs. 2.5%; = 0.735).

CONCLUSION

All in all, the present study could not find the significant differences between the Catania stent and Xience stent in terms of clinical outcomes during the follow-up period.

摘要

背景

本研究旨在比较卡塔尼亚支架与艾可塞尔支架在接受血管成形术患者中的非预期结果。

材料与方法

在一项为期三个月的随访、双盲、随机对照试验中,83例符合纳入标准的接受血管成形术的患者进入研究。随机分组后,43例患者接受艾可塞尔支架治疗,40例患者接受卡塔尼亚支架治疗。比较两组之间与支架相关的结果,如心脏和非心血管死亡、心肌梗死(MI)、靶病变血运重建(TLR)、支架血栓形成(ST)、冠状动脉旁路移植术(CABG)、外周血管病变和脑血管意外(CVA)。

结果

两个治疗组之间并发症发生率和临床结果无统计学显著差异(>0.05)。任何患者均未观察到心肌梗死、靶病变血运重建、冠状动脉旁路移植术、外周血管病变或脑血管意外的发生率,死亡率(4.7%对2.5%;=0.527)和支架血栓形成(2.3%对2.5%;=0.735)无统计学差异。

结论

总而言之,本研究在随访期间未发现卡塔尼亚支架和艾可塞尔支架在临床结果方面存在显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a93/5735554/ad7615950e7f/ABR-6-154-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a93/5735554/ad7615950e7f/ABR-6-154-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a93/5735554/ad7615950e7f/ABR-6-154-g001.jpg

相似文献

1
Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial.与Xience支架相比,卡塔尼亚支架在接受血管成形术患者中的不良后果:一项双盲随机对照试验。
Adv Biomed Res. 2017 Nov 30;6:154. doi: 10.4103/2277-9175.219419. eCollection 2017.
2
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).SPIRIT III 试验的 5 年随机对照研究结果:依维莫司洗脱 XIENCE V 支架与紫杉醇洗脱 Taxus 支架的比较——治疗初发的 native 冠状动脉病变患者的 XIENCE V 依维莫司洗脱冠状动脉支架系统的临床评估。
JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.
3
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.经皮冠状动脉介入治疗后病变长度和血管大小对临床结局的影响:来自 SPIRIT(依维莫司洗脱冠状动脉支架系统 XIENCE V 的临床评估)和 COMPARE(真实世界中第二代依维莫司洗脱和紫杉醇洗脱支架)随机试验的汇总分析。
JACC Cardiovasc Interv. 2011 Nov;4(11):1209-15. doi: 10.1016/j.jcin.2011.07.016.
4
Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials.比较急性和稳定型冠状动脉综合征患者中依维莫司洗脱支架和紫杉醇洗脱支架的疗效:来自 SPIRIT(依维莫司洗脱冠状动脉支架系统的临床评估)和 COMPARE(依维莫司洗脱支架和紫杉醇洗脱支架在日常实践中用于冠状动脉血运重建的比较试验)研究的汇总结果。
JACC Cardiovasc Interv. 2011 Oct;4(10):1104-15. doi: 10.1016/j.jcin.2011.06.018.
5
3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).3 年临床随访结果:新一代西罗莫司洗脱冠状动脉支架系统(XIENCE V)治疗初发冠状动脉病变的 SPIRIT II 临床试验(新一代西罗莫司洗脱冠状动脉支架系统治疗初发冠状动脉病变的临床评估)。
JACC Cardiovasc Interv. 2009 Dec;2(12):1190-8. doi: 10.1016/j.jcin.2009.10.002.
6
Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.XIENCE V 在美国研究中 8061 例患者一年后支架血栓形成和其他主要不良心脏事件的当代发生率和预测因素。
JACC Cardiovasc Interv. 2012 Jun;5(6):626-35. doi: 10.1016/j.jcin.2012.02.014.
7
An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial.冠状动脉血运重建患者中使用无载体可生物降解聚合物西罗莫司洗脱支架与使用耐用聚合物依维莫司洗脱支架的比较:一项随机非劣效性试验的 3 年临床结果。
Sci Rep. 2019 Dec 6;9(1):18549. doi: 10.1038/s41598-019-54964-8.
8
Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial.单纯支架置入术与辅助球囊血管成形术治疗隐静脉桥血管经皮冠状动脉介入治疗:来自 DIVA 试验的见解。
Circ Cardiovasc Interv. 2020 Feb;13(2):e008494. doi: 10.1161/CIRCINTERVENTIONS.119.008494. Epub 2020 Feb 5.
9
[Long term safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of coronary de novo lesions].一种新型腔内凹槽填充可生物降解聚合物西罗莫司洗脱支架治疗冠状动脉初发病变的长期安全性和有效性
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Nov 24;45(11):940-947. doi: 10.3760/cma.j.issn.0253-3758.2017.11.009.
10
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.多部位、多血管病变患者中应用依维莫司洗脱支架和紫杉醇洗脱支架的对比:SPIRIT III 试验(在治疗初发冠状动脉病变患者中对依维莫司洗脱冠状动脉支架系统(EECSS)的 XIENCE V 血管内介入器械的临床评估)和 SPIRIT IV 试验(在治疗初发冠状动脉病变患者中对依维莫司洗脱冠状动脉支架系统的 XIENCE V 血管内介入器械的临床评估)随机临床试验。
JACC Cardiovasc Interv. 2010 Dec;3(12):1229-39. doi: 10.1016/j.jcin.2010.09.014.

本文引用的文献

1
Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.真实世界实践中第二代依维莫司洗脱 Xience V 支架与佐他莫司洗脱 Resolute 支架的安全性和疗效:多中心前瞻性 EXCELLENT 和 RESOLUTE-Korea 注册研究的患者相关和支架相关结局。
J Am Coll Cardiol. 2013 Feb 5;61(5):536-44. doi: 10.1016/j.jacc.2012.11.015. Epub 2012 Dec 26.
2
Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry.在真实世界临床实践中 Catania Polyzene-F 涂层支架的安全性和有效性:来自 ATLANTA 2 注册研究的 12 个月结果。
EuroIntervention. 2012 Jan;7(9):1062-8. doi: 10.4244/EIJV7I9A169.
3
2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial).2 年随访:依维莫司洗脱支架和紫杉醇洗脱支架在日常实践中用于冠状动脉血运重建的随机对照试验。COMPARE(依维莫司洗脱 XIENCE-V 支架与紫杉醇洗脱 TAXUS LIBERTÉ 支架在所有患者中的比较:一项随机开放标签试验)。
J Am Coll Cardiol. 2011 Jun 28;58(1):11-8. doi: 10.1016/j.jacc.2011.02.023. Epub 2011 Apr 21.
4
Novel drug-eluting stents in the treatment of de novo coronary lesions.新型药物洗脱支架治疗初发冠状动脉病变
Vasc Health Risk Manag. 2011;7:103-18. doi: 10.2147/VHRM.S11444. Epub 2011 Feb 25.
5
Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program.依维莫司洗脱冠状动脉支架系统的最新进展:SPIRIT临床试验项目的结果与启示
Vasc Health Risk Manag. 2009;5:1089-97. doi: 10.2147/vhrm.s5618. Epub 2009 Dec 29.
6
A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial.一种耐用聚合物依维莫司洗脱支架与裸金属冠状动脉支架的随机对照研究:SPIRIT首次试验。
EuroIntervention. 2005 May;1(1):58-65.
7
A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial.依维莫司洗脱冠状动脉支架与紫杉醇洗脱冠状动脉支架的随机对照研究:SPIRIT II试验
EuroIntervention. 2006 Nov;2(3):286-94.
8
The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry.真实世界患者中的依维莫司洗脱支架:X-SEARCH(鹿特丹心脏医院评估的Xience V支架)注册研究的6个月随访
J Am Coll Cardiol. 2009 Jul 14;54(3):269-76. doi: 10.1016/j.jacc.2009.05.016.
9
First-in-man 1-year clinical outcomes of the Catania Coronary Stent System with Nanothin Polyzene-F in de novo native coronary artery lesions: the ATLANTA (Assessment of The LAtest Non-Thrombogenic Angioplasty stent) trial.首例人体 1 年临床结果的卡塔尼亚冠状动脉支架系统与纳米多孔聚泽酚 F 在初发原生冠状动脉病变:亚特兰大(评估最新非血栓性血管成形术支架)试验。
JACC Cardiovasc Interv. 2009 Mar;2(3):197-204. doi: 10.1016/j.jcin.2008.12.006.
10
Stent thrombosis.支架内血栓形成
J Assoc Physicians India. 2008 Dec;56:969-79.